Trademark: 79314148
Word
H.F.M BY TICEBA
Status
Registered
Status Code
700
Status Date
Tuesday, January 24, 2023
Serial Number
79314148
Registration Number
6959288
Registration Date
Tuesday, January 24, 2023
Mark Type
3000
Filing Date
Saturday, April 10, 2021
Published for Opposition
Tuesday, November 8, 2022

Trademark Owner History
Dr. Christoph Ganss - Original Registrant

Classifications
5 Pharmaceutical drugs, namely, pharmaceutical drugs for treatment of skin diseases, antibiotics, immune suppressants, anti-inflammatory pharmaceuticals; Pharmaceutical drugs for treatment of disease and disorders of the respiratory system, the gastrointestinal system, the endocrine system, the cardiovascular system, the nervous system, the musculoskeletal system, the urinary system, the integumentary system, the reproductive system, for the treatment of blood diseases and disorders; Pharmaceutical and veterinary preparations for treatment of vertigo, migraine, nausea, vomiting, for treatment of skin diseases, wound healing; Pharmaceutical preparations for anti-aging; Diagnostic agents for medical use; Preparations for medical purposes, namely, for the treatment of skin diseases; Substances for medical use, namely, for regeneration of tissue and anti-inflammation; Stem cells for medical purposes; Stem cells for veterinary purposes; Stem cells for aesthetic purposes, namely, for anti-aging, for use in dermatology procedures; Somatic stem cell therapeutics, namely, for medical therapeutic use; Fibroblasts for medical use; Fibroblasts for aesthetic purposes, namely, for use in dermatology procedures; Pharmaceutical implants, namely, implantable surgery bones, bone grafts, cells, bone marrow; Surgical implants derived from stem cells, namely, surgical implants derived from living tissues and living stem cells; Surgical implants derived from fibroblasts, namely, surgical implants comprised of living fibroblasts tissue cells; Biological tissue for implantation, namely, implants comprising living tissues; Cell growth media for growing cells for medical use; Pharmaceutical preparations for tissue regeneration; Vascular grafts; Living tissue, namely, surgical implants comprised of living tissues; Biotechnologically engineered tissue products, namely, cell sheets/plasters for wound healing/burns, eye lense grafts, bone grafts, biological tissue grafts, human allograft tissue
1 Stem cells for scientific or research use; cell growth media for growing cells for scientific use
44 Medical services relating to the removal, treatment, processing and preservation of medical cells and human tissue, stem cells and bone marrow, also in the field of regenerative medicine, including tissue engineering; medical services in connection with the removal, treatment and processing of human tissue and stem cells, human tissue and stem cell bank services, including in the field of regenerative medicine, including tissue engineering; medical services relating to the cultivation and extraction of stem cells; medical services in connection with the cultivation and extraction of stem cells
42 Stem cell research; scientific research and development and medical research and development in the field of stem cells; Scientific research, testing and analysis services in the field of regenerative medicine and tissue engineering; Scientific research for medical purposes; Medical research; Research and development of new products for others; Consultancy in the field of pharmaceutical research; Providing information on medical and scientific research on pharmaceutical products; Biomedical research; Preparation of reports relating to scientific research, namely, technical writing for others; Research in the field of biotechnology; Research in the field of gene therapy; Research and development in the field of immunology; Research and development in the field of antibodies; Research and development in the field of antibody technology; Research and development in the field of bacteriology; Research and development in the field of gene expression systems; Research and development in the field of vaccines; Research and development services for the pharmaceutical industry; Research and development services in the field of biotechnology; Development of industrial processes, namely, engineering of industrial processes to manufacture stem cells; Development of industrial processes, namely, in the field of regenerative medicine and tissue engineering;Industrial process research in the field of regenerative medicine, tissue engineering, chemical engineering
The mark consists of the wording "H.F.M.", underlined and above the wording "BY TICEBA", all in the color blue. The wording is surrounded by 8 rods having a small ball at each end and alternating in color, with every other one in the color blue and the others in the color green. The color white represents background, outlining, shading, and/or transparent area and is not part of the mark.
The color(s) blue and green is/are claimed as a feature of the mark.

Trademark Events
May 23, 2023
Final Decision Transaction Processed By Ib
May 1, 2023
Final Disposition Notice Sent To Ib
May 1, 2023
Final Disposition Processed
Apr 24, 2023
Final Disposition Notice Created, To Be Sent To Ib
Jan 24, 2023
Notice Of Registration Confirmation Emailed
Jan 24, 2023
Registered-Principal Register
Dec 20, 2022
Notification Of Possible Opposition - Processed By Ib
Nov 30, 2022
Notification Of Possible Opposition Sent To Ib
Nov 30, 2022
Notification Of Possible Opposition Created, To Be Sent To Ib
Nov 8, 2022
Official Gazette Publication Confirmation E-Mailed
Nov 8, 2022
Published For Opposition
Nov 7, 2022
Notification Processed By Ib
Oct 19, 2022
Notification Of Possible Opposition Sent To Ib
Oct 19, 2022
Notice Of Start Of Opposition Period Created, To Be Sent To Ib
Oct 19, 2022
Notification Of Notice Of Publication E-Mailed
Sep 29, 2022
Approved For Pub - Principal Register
Sep 29, 2022
Notification Of Non-Final Action E-Mailed
Sep 29, 2022
Non-Final Action E-Mailed
Sep 29, 2022
Non-Final Action Written
Aug 9, 2022
Teas/Email Correspondence Entered
Aug 9, 2022
Correspondence Received In Law Office
Aug 9, 2022
Assigned To Lie
Jul 13, 2022
Notice Of Revival - E-Mailed
Jul 13, 2022
Teas Response To Office Action Received
Jul 13, 2022
Petition To Revive-Granted
Jul 13, 2022
Teas Petition To Revive Received
Jul 13, 2022
Abandonment Notice E-Mailed - Failure To Respond
Jul 13, 2022
Abandonment - Failure To Respond Or Late Response
Jan 15, 2022
Refusal Processed By Ib
Dec 28, 2021
Non-Final Action Mailed - Refusal Sent To Ib
Dec 28, 2021
Refusal Processed By Mpu
Dec 2, 2021
Non-Final Action (Ib Refusal) Prepared For Review
Dec 1, 2021
Non-Final Action Written
Nov 30, 2021
Assigned To Examiner
Jul 2, 2021
Application Filing Receipt Mailed
Jun 28, 2021
New Application Office Supplied Data Entered
Jun 25, 2021
Sn Assigned For Sect 66a Appl From Ib

Trademark Alertz updated from USPTO on 2030-01-24